Cabazitaxel
As of the edition of 20 October 2026, Cabazitaxel is a small molecule: marketed, first approved in 2010 (US); acts on TUBB, TUBB1 and TUBB2A and 6 more; US protection ended in 2025.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Small molecule
- Brand name
- Jevtana Kit
- First approved
- 17 June 2010 (US)
- Approvals on record
- 11 in 7 regions
- Holder of the most recent approval
- Actavis Llc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals; 7 holders in all
- Registered trials
- 109, 23 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Digestive system; Skin and connective tissue; Hormones; Lungs and airways
US protection
US protection ended in 2025.
The last listed US drug-substance patent ended in 2025. The application that gives this date is held by Sanofi.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| TUBB4A | Tubulin beta-4A chain | P04350 |
| TUBB | Tubulin beta chain | P07437 |
| TUBB4B | Tubulin beta-4B chain | P68371 |
| TUBB3 | Tubulin beta-3 chain | Q13509 |
| TUBB2A | Tubulin beta-2A chain | Q13885 |
| TUBB8 | Tubulin beta-8 chain | Q3ZCM7 |
| TUBB6 | Tubulin beta-6 chain | Q9BUF5 |
| TUBB2B | Tubulin beta-2B chain | Q9BVA1 |
| TUBB1 | Tubulin beta-1 chain | Q9H4B7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 3 | 0 | 0 |
| Phase 1 | 13 | 10 | 1 | 2 |
| Phase 2 | 75 | 37 | 13 | 20 |
| Phase 3 | 14 | 8 | 3 | 1 |
| Phase 4 | 4 | 4 | 0 | 0 |
| All trials | 109 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sanofi | Originator, Applicant and Lead sponsor of trials | 1999 to now |
| Accord Healthcare | Later holder | 2021 to now |
| Sandoz | Later holder | 2023 to now |
| Actavis Llc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals | Later holder | 2024 to now |